Mekinist (trametinib) / Novartis, Japan Tobacco, BeiGene  >>  Phase 2
Welcome,         Profile    Billing    Logout  

116 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mekinist (trametinib) / Novartis, BeiGene
2020-005053-25: To test the safety, efficacy and tolerability of a drug called trametinib and determine the duration of treatment in children with histiocytic cell hyperplasia refractory to conventional therapy. Sprawdzenie bezpieczeństwa, skuteczności i tolerancji leku o nazwie trametinib oraz określenie czasu leczenia u dzieci z opornymi na konwencjonalną terapię rozrostami z komórek histiocytarnych.

Not yet recruiting
2
12
Europe
Mekinist, Coated tablet, Mekinist
Institute of Mother and Child, Medical Research Agency
histiocytic cell proliferation rozrost komórek histiocytarnych, Neoplasm derived from histiocyte Nowotwór pochodzacy z histiocytów, Diseases [C] - Cancer [C04]
 
 
2019-003573-26: Evaluating the safety and efficacy of Trametinib in Arterio-Venous Malformations that are refractory to standard care

Not yet recruiting
2
20
Europe
Mekinist, Coated tablet, Mekinist
Cliniques universitaires Saint-Luc, Novartis
Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated, Arteriovenous Malformations, Diseases [C] - Cardiovascular Diseases [C14]
 
 
ACTRN12620001229965: TiNT: Trametinib in Neurofibromatosis type 1 associated tumours

Recruiting
2
120
 
Australian and New Zealand Children's Haematology/Oncology Group, Flicker of Hope Foundation Ltd, National Health and Medical Research Council., Wayne Francis Charitable Trust
Plexiform neurofibromatosis, Optic pathway glioma, Neurofibromatosis type 1
 
 
2013-002616-28: A trial with patients who have a tumor that is too big to resect via operation, to treat them with systemic treatment to downsize the tumor, so that after 8 weeks the tumor can be resected and the patient is cured.

Ongoing
2
25
Europe
dabrafenib, trametinib, GSK2118436, GSK1120212, Capsule, Tablet
NKI-AVL, GlaxoSmithKline
unresectable stage III/IV melanoma, skin cancer that has spread out through the body, Diseases [C] - Cancer [C04]
 
 
2013-004966-33: A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanoma

Ongoing
2
25
Europe
Dabrafenib, Trametinib, GSK1120212, Capsule, Film-coated tablet, Tafinlar
UZ Brussel, UZ Brussel
advanced BRAF V600 mutant melanoma, advanced BRAF V600 mutant melanoma, Diseases [C] - Cancer [C04]
 
 
NCT02281734: Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease and BRAF Mutation

Recruiting
2
18
US
dabrafenib, BRAF inhibitor GSK2118436, GSK-2118436A, GSK2118436, Tafinlar, trametinib, GSK1120212, JTP-74057, Mekinist, laboratory biomarker analysis, quality-of-life assessment, quality of life assessment, questionnaire administration
National Cancer Institute (NCI)
Erdheim-Chester Disease
02/15
 
NCT02402790: A Comparative Study Efficacy of Trametinib (CT) in Comparison With Trametinib (MEKINIST)

Active, not recruiting
2
202
Europe, RoW
Trametinib, Trametinib (CT), Mekinist, GSK1120212
Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation
Cancer
03/15
04/17
NCT01951495: A Study of Trametinib and GSK2141795 Multiple Myeloma

Not yet recruiting
2
74
Canada
Trametinib, GSK1120212, GSK2141795
University Health Network, Toronto, National Cancer Institute (NCI)
Multiple Myeloma, Relapsed, Refractory
10/15
03/16
2013-003452-21: Open-Labeled Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. Estudio abierto de dabrafenib en combinación con trametinib en pacientes con melanoma BRAF positivo y metástasis cerebrales.

Ongoing
2
30
Europe
Tafinlar, Trametinib, GSK1218436, GSK1120212, Tafinlar, Tafinlar
GlaxoSmithKline, S.A., GlaxoSmithKline Research & Development Ltd, GSK USA
Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain Pacientes con melanoma BRAF positivo y metástasis cerebrales.
 
 
2016-002941-49: This is a pilot study (n=35 patients in total in two arms) testing the hypothesis that the inhibition of MEK can restore iodine incorporation in BRAF wild type (n=25 patients) and a combined inhibition of BRAF and MEK can restore iodine incorporation in BRAFV600E mutant (n=10 patients), radioiodine-refractory (RAIR) thyroid cancer.

Not yet recruiting
2
35
Europe
Mekinist®, Tafinlar, EU/1/14/931/06, EU/1/13/865/005, EU/1/14/931/02, EU/1/13/865/002, Film-coated tablet, Capsule, hard, Mekinist ®, Tafinlar®
University Hospital Essen (Anstalt des öffentlichen Rechts)
Radio Iodine Refractory Thyroid Cancer, Thyroid cancer, Diseases [C] - Cancer [C04]
 
 
ACTRN12613000737730: An open label, single centre, phase II pilot study of neoadjuvant dabrafenib + trametinib in patients with resectable AJCC Stage IIIB-C BRAF V600 mutation positive melanoma

Active, not recruiting
2
35
 
Melanoma Institute Australia, GlaxoSmithKline Australia
Melanoma
 
 
Neo Combi, NCT01972347: Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
2
35
RoW
Dabrafenib, GSK2118436, Trametinib, GSK1120212
Melanoma Institute Australia
Melanoma
05/17
05/24
NCT02199730: S1320: Intermittent Versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E/K Mutant Melanoma

Recruiting
2
280
US
Dabrafenib, Dabrafenib Mesylate (GSK2118436, GSK2118436A) (NSC-763760), Tafinlar, Trametinib, Trametinib Dimethyl Sulfoxide (GSK1120212B) (NSC-763093), Mekinist
Southwest Oncology Group, National Cancer Institute (NCI)
Melanoma
10/17
07/21
2016-005228-27: A trial to compare giving chemotherapy intermittently to chemotherapy administered continuously to patients with inoperable or metastatic melanoma.

Not yet recruiting
2
150
Europe
dabrafenib, trametinib, Capsule, hard, Film-coated tablet, dabrafenib, trametinib
Cambridge University Hospitals NHS Foundation Trust, National Institute for Health Research
BRAFV600 mutant stage 3 unresectable or metastatic melanoma, Advanced melanoma (skin cancer) which has an abnormal gene called BRAF., Diseases [C] - Cancer [C04]
 
 
2018-004003-39: A trial to assess efficacy in patients with advanced pretreated BRAFV600 wild-type melanoma

Not yet recruiting
2
58
Europe
Trametinib, Dabrafenib, GSK1120212, L01XE23, Film-coated tablet, Capsule, hard, Mekinist (Trametinib), Tafinlar
UZ Brussel, UZ Brussel
ADVANCED PRETREATED BRAFV600 WILD-TYPE MELANOMA, ADVANCED PRETREATED BRAFV600 WILD-TYPE MELANOMA, Diseases [C] - Cancer [C04]
 
 
NCT04439279: Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Active, not recruiting
2
35
US
Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
03/19
03/25
NCT02642042: Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Active, not recruiting
2
60
US
Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Laboratory Biomarker Analysis, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
05/19
03/25
2019-001317-16: The TRAIN study: TRAmetinib In Neurofibromatosis type 1 related symptomatic plexiform neurofibromas De TRAIN studie: TRAmetinib voor Neurofibromatose type 1 gerelateerde pleximorme neurofibromen

Ongoing
2
30
Europe
Film-coated tablet, Mekinist
ErasmusMC, Stichting NF, Novartis
Adult patients (age >17 years) with (mosaic) NF1 with inoperable symptomatic plexiform neurofibromas, Adult patients (age >17 years) with (mosaic) NF1 with inoperable symptomatic plexiform neurofibromas, Diseases [C] - Nervous System Diseases [C10]
 
 
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig

Not yet recruiting
2
30
Europe
Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo
Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark
Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04]
 
 
NCT04439318: Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Active, not recruiting
2
50
US
Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
06/20
12/25
NCT04439357: Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Active, not recruiting
2
4
US
Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
09/20
12/25
2020-004414-35: Improving public cancer care by implementing precision medicine in Norway

Not yet recruiting
2
2000
Europe
Alpelisib, Fulvestrant, imatinib, Hydroxyurea, bortezomib, capmatinib, Dactinomycin, tepotinib, dostarlimab, Capsule, hard, Injection, Infusion, Tablet, Capsule, Solution for injection, Powder and solvent for suspension for injection, Powder for solution for injection, Concentrate for solution for infusion, Alecensa, Erivedge, Phesgo, Rozlytrek, Tecentriq, Avastin, Zelboraf, Cotellic, Mekinist, Tafinlar, Alkeran, Piqray, Lynparza, Pemazyre, Tabrecta, Retsevmo, Tepmetko, Gavreto, Zejula
Oslo University Hospital, Oslo University Hospital
Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible., Patients with a biomarker indicating response to the study drug can be included in the trial. Patients with disease characteristics covered in present indications for the study drug are not eligible., Diseases [C] - Cancer [C04]
 
 
2021-000087-30: Treatment with the drugs dabrafenib and trametinib before or afteroperation for the tumour papillary craniopharyngioma Behandling med medicinerna dabrafenib och trametinib före eller efteroperation av tumören papillärt kraniopfaryngeom

Not yet recruiting
2
25
Europe
Capsule, hard, Film-coated tablet, Tafinlar, Mekinist
Skane University Hospital, Dept of Endocrinology, Region Skåne, Skane University Hospital
Papillary craniopharyngioma Papillärt kraniofaryngeom, Craniopharyngeoma, benign tumour near the pituitary and hypothalamus Kraniofaryngeom, en godartad tumör belägen vid hypofysen och hypothalamus, Diseases [C] - Cancer [C04]
 
 
2021-001375-16: Study of the effectiveness of drugs selected depending on the molecular profile of diffuse intrinsic pontine glioma (DIPG) Badanie skuteczności leków dobranych w zależności od profilu molekularnego rozlanego glejaka pnia mózgu (diffuse intrinsic pontine glioma, DIPG)

Not yet recruiting
2
100
Europe
Film-coated tablet, Coated tablet, , Mekinist 0,5 mg film-coated tablets, Rapamune 1 mg coated tablets, Rapamune 1mg/ml oral solution
The Children's Memorial Health Institute, Medical Research Agency
diffuse intrinsic pontine glioma rozlany naciekający glejak mostu, brain stem tumor guz pnia mózgu, Diseases [C] - Cancer [C04]
 
 
CDRB436G2201, NCT02684058 / 2015-004015-20: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Checkmark From trial in combination with Tafinlar in BRAF V600mutant glioma
Jun 2022 - Jun 2022: From trial in combination with Tafinlar in BRAF V600mutant glioma
Completed
2
151
Europe, Canada, Japan, US, RoW
Dabrafenib, DRB436, trametinib, TMT212, Carboplatin, Vincristine
Novartis Pharmaceuticals
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma
08/21
04/23
NCT02152995: Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Active, not recruiting
2
34
US
Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Iodine I 124, I-124, Iodine 124, Iodine I-124, Iodine I-131, 131-Iodine, Bound Iodide I-131, I 131, I-131, Iodide I-131, Iodide, I-131, Iodine 131, Iodine-131, Iodotope, Iodotrope, Laboratory Biomarker Analysis, Pharmacodynamic Study, PHARMACODYNAMIC, Pharmacodynamic (PD) study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
08/21
01/25
2021-000689-14: Finnish national phase 2 study to evaluate targeted drug treatment in advanced cancer. Yksilöllistä syövänhoitoa selvittävä kansallinen vaiheen 2 lääketutkimus edenneessä syövässä.

Not yet recruiting
2
250
Europe
abemaciclib, pralsetinib, Tablet, Capsule, hard, Injection, Infusion, Capsule, Stivarga, Alecensa, Cotellic, Erivedge, Phesgo, Rozlytrek, Tecentriq, Zelboraf, Verzenios, Retsevmo, Erleada, Tafinlar, Mekinist, Gavreto, Lynparza
Helsinki University Hospital, Helsinki University Hospital
Patients with an advanced solid tumor for which standard treatment options no longer exist and with acceptable performance status and organ function with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test., Patients with advanced cancer where standard treatment options no longer exist. Potilaat, jotka sairastava edennyttä syöpää, johon tavanomaiset hoitolinjat eivät enää tehoa., Diseases [C] - Cancer [C04]
 
 
2020-005786-14: A randomized and controlled phase II national protocol in non NF1 pediatric and AYA (Adolescent and Young Adults) patients bearing a wild type BRAF gene newly diagnosed comparing a daily oral MEK inhibitor (Trametinib) versus weekly vinblastine during 18 monthsPLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy) Protocole national de phase II des patients pédiatriques et AJA (Adolescents et Jeunes Adultes) non NF1 ayant un gliome de bas grade BRAF non muté en première ligne comparant un traitement par MEK inhibiteur (Trametinib) en prise orale quotidienne versus vinblastine IV hebdomadaire pendant 18 mois

Not yet recruiting
2
134
Europe
MEKINIST, Trametinib 5mg poudre pour solution buvable, Tablet, Powder for solution for injection, Powder for oral solution, MEKINIST, VELBE
Hôpitaux Universitaires de Strasbourg B.1.2, Hôpitaux universitaires de Strasbourg
Histologically proven grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocytoma (PXA) confirmed Gliome de grade 1 / tumeurs glio-neuronales mixtes ou xanthoastrocytome pléomorphe (PXA) histologiquement prouvé et confirmé, Pediatric Low Grade Glioma Gliome de bas grade pédiatrique, Diseases [C] - Cancer [C04]
 
 
MERAIODE, NCT03244956 / 2017-000742-21: Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Active, not recruiting
2
40
Europe
Trametinib, Dabrafenib, 131I, rhTSH
Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
11/21
12/22
COMBI-R2, NCT03754179: Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma

Recruiting
2
63
Europe
Dabrafenib, Tafinlar, DAB, Trametinib, Mekinist, TRA, Hydroxychloroquine, Plaquenil, HCQ
Universitair Ziekenhuis Brussel, University Hospital, Ghent
Melanoma
12/21
07/22
NCT04554680: Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

Recruiting
2
5
RoW
dabrafenib and trametinib
National University Hospital, Singapore, Singapore General Hospital
Thyroid Cancer
12/21
04/22
NCT03149029: Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

Active, not recruiting
2
16
US
Pembrolizumab, Keytruda, Dabrafenib, Tafinlar, Trametinib, Mekinist
Massachusetts General Hospital, Merck Sharp & Dohme LLC
Metastatic Melanoma
12/21
12/24
NeoTrio, NCT02858921: Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Active, not recruiting
2
60
RoW
Dabrafenib, Tafinlar, Trametinib, Mekinist, Pembrolizumab, Keytruda
Melanoma Institute Australia, Merck Sharp & Dohme LLC, Novartis
Melanoma
01/22
11/24
2021-006276-16: A phase 2 clinical research study to examine if trametinib and hydroxychloroquine will improve outcomes for patients with advanced pancreatic cancer.

Not yet recruiting
2
22
Europe
Trametinib, Hydroxychloroquine sulfate, Film-coated tablet, Mekinist®, Hydroxychloroquine sulfate
Cancer Trials Ireland, Cancer Trials Ireland
Metastatic refractory pancreatic cancer., Advanced pancreatic cancer., Diseases [C] - Cancer [C04]
 
 
NCT01723202: Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer

Active, not recruiting
2
53
US
dabrafenib, BRAF inhibitor GSK2118436, GSK2118436, trametinib, GSK1120212, MEKi, Correlative Studies, Pharmacological studies, Tumor pharmacodynamics, PD, PK, PGx
Bhavana Konda, National Comprehensive Cancer Network
Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer
04/22
12/22
NCT04566133: Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Terminated
2
2
US
Trametinib, Mekinist, Hydroxychloroquine, Plaquenil
National Cancer Institute (NCI)
Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
05/22
12/22
Nov IIT- Pyrex, NCT04652258: Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated With Dabrafenib/ Trametinib +/- Immunotherapy

Recruiting
2
20
Europe
Actemra
University of Zurich
Pyrexia
06/22
10/22
NCT03668431: Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Recruiting
2
25
US
Dabrafenib, Tafinlar®, Trametinib, Mekinist®, PDR001
Massachusetts General Hospital, Novartis, Stand Up To Cancer
Metastatic Colorectal Cancer
09/22
12/22
2022-001908-17: Neo- and adjuvant targeted therapy in anaplastic cancer of the thyroid (NEO-ATACT study) Neo-adjuvante en adjuvante behandeling voor anaplastisch carcinoom van de schildklier (NEO-ATACT studie)

Ongoing
2
20
Europe
Capsule, hard, Tablet, Tafinlar, Mekinist
Leiden University Medical Center, Norvartis
BRAF-mutated anaplastic thyroid cancer, Anaplastic thyroid cancer with BRAF mutation, Diseases [C] - Cancer [C04]
 
 
INDIGO, NCT04644432: Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

Recruiting
2
30
Europe
Medication (A specification is listed under each arm), Patient reported outcomes measurement, PRO
Herlev and Gentofte Hospital
Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms, Urogenital Neoplasms
09/22
09/22
NCT04487106: Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Completed
2
21
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
02/23
02/23
NCT05299580 / 2019-004760-21: "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Withdrawn
2
35
Europe
dabrafenib, Trametinib
Fondazione Melanoma Onlus, Novartis Farma S.p.A.
Melanoma
03/23
03/23
ADVL1521, NCT03190915: Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Active, not recruiting
2
10
US
Bone Marrow Aspiration and Biopsy, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI), Children's Oncology Group
Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
03/23
09/24
CAcTUS, NCT03808441: - Circulating Tumour DNA Guided Switch

Active, not recruiting
2
21
Europe
ctDNA analysis
The Christie NHS Foundation Trust, Bristol-Myers Squibb, University of Manchester, Manchester Academic Health Science Centre
Melanoma
04/23
05/24
SARC033, NCT03148275: Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

Completed
2
44
US
Questionnaire Administration, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma, Unresectable Epithelioid Hemangioendothelioma
06/23
06/23
TraMel-WT, NCT04059224: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma

Completed
2
45
Europe
Trametinib, TRA, Mekinist, Dabrafenib, DAB, Tafinlar
Universitair Ziekenhuis Brussel
Stage IV Melanoma, Stage III Melanoma
06/23
06/23
plexifpc, NCT03741101 / 2018-001846-32: Treatment of NF1-related Plexiform Neurofibroma With Trametinib

Active, not recruiting
2
15
Europe
Trametinib, mekinist
Region Skane, Novartis
Neurofibromatosis 1, Child, Neurofibroma, Plexiform
07/24
12/24
NCI-2020-03273, NCT04439292: Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Active, not recruiting
2
35
US
Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
04/25
04/25
ALTER-PATH NeoDT, NCT04310397: Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Completed
2
4
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Spartalizumab, PDR-001, PDR001, Therapeutic Conventional Surgery, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
10/23
10/23
NCT02196181: Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Active, not recruiting
2
280
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
12/24
12/24
ANAPLAST-NEO, NCT04739566: Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer

Withdrawn
2
18
RoW
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
Saint Petersburg State University, Russia
Thyroid Gland Anaplastic Carcinoma
12/23
12/23
NCT03087071: Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

Active, not recruiting
2
59
US
Laboratory Biomarker Analysis, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, MoAb ABX-EGF, Monoclonal Antibody ABX-EGF, Vectibix, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
01/25
01/25
NCT02881242: Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Active, not recruiting
2
14
US
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
Jonsson Comprehensive Cancer Center, Stand Up To Cancer, Novartis, Prostate Cancer Foundation
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
01/24
01/25
NCT06362694: Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

Recruiting
2
10
RoW
Dabrafenib + Trametinib
Saint Petersburg State University, Russia
Anaplastic Thyroid Cancer
03/26
06/26
Combi-Neo, NCT02231775: Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Active, not recruiting
2
58
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
04/25
04/25
NCT04417621 / 2020-000873-26: Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Active, not recruiting
2
134
Europe, US, RoW
LXH254, LTT462, Trametinib, Ribociclib
Novartis Pharmaceuticals
Melanoma
08/24
09/24
MEMBRAINS, NCT03563729 / 2018-000875-34: Melanoma Metastasized to the Brain and Steroids

Recruiting
2
80
Europe
Pembrolizumab Injection [Keytruda], Ipilimumab Injection [Yervoy], Nivolumab Injection [Opdivo], Encorafenib, Binimetinib, Dabrafenib, Trametinib
Inge Marie Svane
Malignant Melanoma
06/24
06/28
NCT04238624: Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Recruiting
2
15
US
Dabrafenib, Trametinib
Memorial Sloan Kettering Cancer Center
Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related Tumors
06/24
06/24
NCT04675710: Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Recruiting
2
30
US
Conventional Surgery, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center
Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma
06/24
06/24
PaTcH, NCT05518110: Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

Recruiting
2
22
Europe
Trametinib, Hydroxychloroquine
Cancer Trials Ireland, Novartis
Pancreatic Cancer
07/24
04/25
NCT01990196: Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Active, not recruiting
2
45
US
degarelix, Firmagon, FE200486, enzalutamide, Xtandi, MDV3100, trametinib, Mekinist, dasatinib, Sprycel, BMS-354825
Jonsson Comprehensive Cancer Center, Medivation, Inc., GlaxoSmithKline, Prostate Cancer Foundation, Astellas Pharma Inc, Novartis
Prostate Cancer
09/24
09/25
NCT04452877: A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Active, not recruiting
2
40
RoW
Dabrafenib, DRB436, Trametinib, TMT212
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
11/24
11/24
RegoMel, NCT05370807: A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma

Recruiting
2
48
Europe
Regorafenib 40 MG Oral Tablet, Triplet therapy
Universitair Ziekenhuis Brussel
Melanoma Stage III, Melanoma Stage IV
12/24
03/25
TRIDeNT, NCT02910700: Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Active, not recruiting
2
52
US
Binimetinib, Dabrafenib, Encorafenib, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study, Trametinib
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
12/24
12/24
I-FIRST, NCT05182931: A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer ( Study)

Recruiting
2
80
RoW
Dabrafenib 75 MG, Tafinlar, Trametinib 2 MG, Mekinist
Olivia Newton-John Cancer Research Institute, Royal North Shore Hospital, Austin Health, Sir Charles Gairdner Hospital, Monash Health, Peter MacCallum Cancer Centre, Australia, Royal Brisbane and Women's Hospital, Eastern Health, The Alfred, Royal Adelaide Hospital
Thyroid Cancer
12/24
12/25
ERRITI, NCT04619316: Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

Recruiting
2
70
Europe
Trametinib 2 MG [Mekinist], Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]
University Hospital, Essen
Metastatic Thyroid Cancer
12/24
12/24
NCT04258046: Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

Recruiting
2
30
US
Trametinib tablet
Stanford University, Boston Children's Hospital
Venous Malformation, Arterial Disease
12/24
12/24
NCT04803318: Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Recruiting
2
100
RoW
Combination of three inhibitors Trametinib, Everolimus and Lenvatinib, Combination of 3 signaling pathway inhibitors specific to MEK, mTOR, and angiogenesis.
Second Affiliated Hospital of Guangzhou Medical University
Solid Tumor, Adult, Hepatocellular Carcinoma
01/29
01/37
NCT06054191: Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

Not yet recruiting
2
40
RoW
Dabrafenib + Trametinib, Capmatinib
Sun Yat-sen University
NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation
03/25
03/27
CA209-8TT, NCT03899155 / 2018-004362-34: Pan Tumor Rollover Study

Recruiting
2
1500
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558-01, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, BMS-986016-01, Nivolumab + Relatlimab, BMS-986213, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
Bristol-Myers Squibb, Exelixis, Novartis, Clovis Oncology, Inc., Janssen Pharmaceuticals
Cancer
08/29
08/29
NCT04544111: PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Active, not recruiting
2
19
US
Trametinib, Dabrafenib, PDR001
Memorial Sloan Kettering Cancer Center
Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Hurthle Cell Thyroid Neoplasia
09/25
09/25
OZUHN-017, NCT06098872: Pilot Study on Trametinib for Surgical Unruptured AVMs

Recruiting
2
10
Canada
Trametinib tablet
University Health Network, Toronto
Arteriovenous Malformations
11/25
11/25
NCT04527549: Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Active, not recruiting
2
84
US
Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Hydroxychloroquine Sulfate, Plaquenil, Placebo Administration, Trametinib Dimethyl Sulfoxide
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
11/25
11/25
NCI-MATCH, NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Checkmark Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
Nov 2019 - Nov 2019: Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
Active, not recruiting
2
6452
US, RoW
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Afatinib, BIBW 2992, BIBW-2992, BIBW2992, Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif, Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capivasertib, AZD5363, Truqap, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Defactinib, PF-04554878, VS-6063, Defactinib Hydrochloride, Echocardiography, EC, Erdafitinib, Balversa, JNJ-42756493, Fexagratinib, ABSK-091, ABSK091, AZD4547, FGFR Inhibitor AZD4547, KB-74810, Ipatasertib, GDC-0068, RG-7440, Laboratory Biomarker Analysis, Larotrectinib, ARRY 470, LOXO 101, LOXO-101, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Osimertinib, AZD-9291, AZD9291, Mereletinib, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, PI3K-beta Inhibitor GSK2636771, GSK-2636771, GSK2636771, Radiologic Examination, Radiologic Evaluation, Radiologic Exam, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Sunitinib Malate, SU011248, SU11248, sunitinib, Sutent, Taselisib, GDC-0032, RO5537381, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herzuma, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Ulixertinib, BVD-523, VRT752271, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Recurrent Uterine Corpus Cancer, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma, Uterine Corpus Cancer
12/25
12/25
MegaMOST, NCT04116541: A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Recruiting
2
455
Europe
HDM201, Closed cohort, Ribociclib, Cabozantinib, Open cohort, Alectinib, Regorafenib, Trametinib, Dabrafenib, Avapritinib
Centre Leon Berard
Malignant Solid Tumor
02/26
11/26
NCT05876806: Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Recruiting
2
30
RoW
Dabrafenib, Trametinib
Se Jun Park
Cancer
03/26
03/26
TRAM, NCT04943224: Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

Recruiting
2
12
Europe
Trametinib, Mekinist
Anna Raciborska, Maria Sklodowska-Curie National Research Institute of Oncology, Łukasiewicz Research Network, Wrocław University of Environmental and Life Sciences
Histiocytosis
03/26
06/26
NCT05988697: Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting
2
36
NA
Combind asprin with Trametinib and Dabrafenib
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NSCLC, BRAF V600E Mutation, Advanced Cancer, Stage IIIB NSCLC, Stage IV NSCLC
09/26
04/27
FINPROVE, NCT05159245: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Recruiting
2
250
Europe
Alectinib, Alecensa, Cobimetinib, Cotellic, Vismodegib, Erivedge, Trastuzumab+Pertuzumab, Phesgo, Entrectinib, Rozlytrek, Atezolizumab, Tecentriq, Vemurafenib, Zelboraf, Regorafenib, Stivarga, Apalutamide, Erleada, Abemaciclib, Verzenio, Selpercatinib, Retevmo, Dabrafenib, Tafinlar, Trametinib, Mekinist, Dabrafenib+Trametinib, Tafinlanr+Mekinist, Pralsetinib, Gavreto
Helsinki University Central Hospital
Advanced Cancer, Solid Tumor, Haematological Malignancy
11/26
11/26
NEO-ATACT, NCT06079333: NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid ( Study)

Recruiting
2
20
Europe
dabrafenib/trametinib
Leiden University Medical Center, Novartis
Anaplastic Thyroid Cancer
01/27
01/28
TRAM-01, NCT03363217: Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Active, not recruiting
2
114
Canada
Trametinib, Mekinist
St. Justine's Hospital, Montreal Children's Hospital of the MUHC, CHU de Quebec-Universite Laval
Low-grade Glioma, Plexiform Neurofibroma, Central Nervous System Glioma
03/27
03/27
MatchMel, NCT02645149: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

Recruiting
2
1000
RoW
Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study
Melanoma Institute Australia, Novartis
Melanoma
07/27
12/28
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Swecranio, NCT05525273: Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma

Recruiting
2
25
Europe
Oral dabrafenib and trametinib
Eva Marie Erfurth, MD, PhD, Novartis
Craniopharyngioma
09/27
04/28
NCT03919071: Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Recruiting
2
58
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Lumbar Puncture, LP, Spinal Tap, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma
09/27
09/27
PLGG - MEKTRIC, NCT05180825: Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

Recruiting
2
134
Europe
Trametinib, Vinblastine
University Hospital, Strasbourg, France
Grade 1 Glioma, Mixed Glio-neuronal Tumors, Pleomorphic Xanthoastrocytoma
11/31
12/31
2021-003398-79: International study in which the idea is to use the abnormalities of the bloodtumor of children, that is either not responsive to standard therapy or has returned, as a starting point for a new therapy. Internationale studie waarin het idee is om de afwijkingen van de bloedtumor bij kinderen, die of ongevoelig is voor standaard therapie of die is teruggekomen, te gebruiken als vertrekpunt voor een nieuwe behandeling.

Not yet recruiting
1/2
26
Europe
Trametinib, TMT212, Film-coated tablet, Powder for oral solution, Mekinist
Princess Máxima Center for pediatric oncology, European Science Foundation - Fight Kids Cancer
Molecularly profiled r/r ALL/LBL whose tumor harbors an actionable event that can be targeted by the investigational agents. In this subprotocol, patients must present alterations in the RAS signaling pathway. Moleculaire geprofileerde r/r/ ALL/LBL waarvan de tumor een target heeft voor de onderzoeksmedicatie. In dit sub-protocol moet de tumor een verandering hebben in de RAS signaal transductie route., relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) with activating mutations of the RAS signaling pathway recidief of refractaire acute lymfatische leukemie (ALL) of lymfoblastisch lymfoom(LL) met activerende mutaties van het RAS-signaalpad., Diseases [C] - Cancer [C04]
 
 
2019-001399-13: MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEL Etude de phase I/II évaluant la tolérance d’un traitement par hydroxychloroquine associé au tramétinib dans le mélanome NRAS muté métastatique ou localement avancé non résécable après échec d’une immunothérapie. CHLORO TRAM MEL

Not yet recruiting
1/2
29
Europe
Trametinib, Sulfate d'hydroxychloroquine, Tablet, Mekinist, Plaquenil
Hospices Civils de Lyon, Health ministry, Novartis
Patients with metastatic NRAS melanoma, Patients with metastatic NRAS melanoma, Diseases [C] - Cancer [C04]
 
 
2014-002209-39: Phase I/II study with lapatinib plus trametinib in patients with metastatic non-small cell lung cancer with a mutation in the KRAS gene Fase I/II studie met de combinatie van lapatinib met trametinib bij patiënten met uitgezaaid niet kleincellig longkanker met een KRAS genmutatie

Ongoing
1/2
132
Europe
Lapatinib, trametinib, docetaxel, Tablet, Film-coated tablet, Concentrate and solvent for concentrate for solution for infusion, Mekinist
The Netherlands Cancer Institute, Novartis
non-small cell lung cancer niet-kleincellig longkanker, lung cancer longkanker, Diseases [C] - Cancer [C04]
 
 
NCT01970956: Dabrafenib/Trametinib/Navitoclax In Braf Mutant Melanoma

Not yet recruiting
1/2
18
US
Navitoclax, ABT-263, Dabrafenib, GSK2118436, GSK2118436A (free base), Tafinlar, Trametinib, GSK1120212, JTP-74057, JTP-78296, JTP-75303, Mekinist
Massachusetts General Hospital, National Cancer Institute (NCI)
BRAF Mutant Melanoma, Solid Tumors
01/17
09/20
SWOG-S1221, NCT01902173: Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Active, not recruiting
1/2
27
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel, Uprosertib, GSK2141795, Oral Akt Inhibitor GSK2141795
National Cancer Institute (NCI), GlaxoSmithKline, Novartis Pharmaceuticals
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
05/18
10/24
2019-004819-31: First in human study assessing the safety, immunogenicity and efficacy of the cancer vaccine IN01 as second line of treatment in RAS and BRAF mutated metastatic colorectal cancer patients

Not yet recruiting
1/2
70
Europe
trametinib, encorafenib, IN01, Emulsion and suspension for emulsion for injection, Tablet, Capsule, hard, MEKINIST, BRAFTOVI
IN3BIO, IN3BIO
colorectal cancer at a metastatic stage, eligible for a second line treatment and presenting with a constitutive BRAF or RAS mutation, patients with a colorectal cancer with distant metastasis and laboratory identified BRAF or RAS constitutive tumour mutations eligible to receive a second line treatment, Diseases [C] - Cancer [C04]
 
 
2021-006196-42: Study of JDQ443 , in combination with trametinib or ribociclib or cetuximab, in advanced cancer with a specific mutation (changes in a gene) called KRAS G12C

Not yet recruiting
1/2
450
Europe
JDQ443, TMT212, ribociclib, cetuximab, JDQ443, TMT212, LEE011, Tablet, Film-coated tablet, Solution for infusion, Mekinist, Kisqali, Erbitux
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors, advanced cancer with a specific mutation (G12C) in the KRAS gene, Diseases [C] - Cancer [C04]
 
 
2021-005167-51: A trial to determine the safety of CC-92480 when combined with novel compounds in people who have Multiply Myeloma that is not responsive after treatment or has returned after a period of treatment Un ensayo para determinar la seguridad de CC-92480 cuando se combina con compuestos novedosos en personas con mieloma múltiple que no responde después del tratamiento o ha regresado después de un período de tratamiento

Not yet recruiting
1/2
60
Europe
CC-92480, BET-Inhibitor, Tazemetostat (Tazverik), Trametinib Mekinist, Dexamethasone, BMS-986158, TMT212, Capsule, hard, Capsule, Tablet, Tazemetostat (Tazverik), Trametinib Mekinist
Celgene Corporation, Celgene Corporation
Relapsed or Refractory Multiple Myeloma (RRMM) Mieloma múltiple recidivante o resistente (MMRR), Cancer of plasma cells Cancer de células plasmáticas, Diseases [C] - Cancer [C04]
 
 
TRIDENT-2, NCT05071183: A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Hourglass Jan 2023 - Dec 2023 : Data readout from P1b/2 TRIDENT-2 trial in combination with trametinib for KRAS mutant solid tumors
Terminated
1/2
9
US
TPX-0005, repotrectinib, Trametinib, Mekinist
Turning Point Therapeutics, Inc.
KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor
03/23
03/23
NCT04326283: Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
1/2
23
RoW
Trametinib (0.5 mg), Meqsel, SNR1611, Trametinib (1 mg), Riluzole (100 mg), Yooritek
Genuv Inc.
Amyotrophic Lateral Sclerosis
04/23
04/23
NCT02079740: Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
97
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
12/22
03/25
NCI-2013-02103, NCT01989585: Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Active, not recruiting
1/2
75
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Echocardiography, EC, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Pharmacological Study, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
12/24
12/24
CheckMate 9N9, NCT03377361 / 2017-001830-24: An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

Active, not recruiting
1/2
232
Europe, Canada, US, RoW
Nivolumab, Opdivo, BMS-936558, Trametinib, Mekinist, Ipilimumab, Yervoy, BMS-734016, Regorafenib
Bristol-Myers Squibb, Novartis
Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
03/24
03/24
NCT04892017: A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Recruiting
1/2
173
US
DCC-3116, Trametinib, Binimetinib, Sotorasib
Deciphera Pharmaceuticals LLC
Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
08/27
08/28
 

Download Options